Outcome of Patients Who Refuse Cystectomy after Receiving Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer
- 31 July 2008
- journal article
- Published by Elsevier BV in European Urology
- Vol. 54 (1), 126-132
- https://doi.org/10.1016/j.eururo.2007.12.031
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Assessing interactions between mdm-2, p53, and bcl-2 as prognostic variables in muscle-invasive bladder cancer treated with neo-adjuvant chemotherapy followed by locoregional surgical treatmentAnnals of Oncology, 2006
- Neoadjuvant Chemotherapy in Invasive Bladder Cancer: Update of a Systematic Review and Meta-Analysis of Individual Patient DataEuropean Urology, 2005
- p53 and p21 expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined‐modality approachCancer, 2004
- Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder CancerNew England Journal of Medicine, 2003
- Can patient selection for bladder preservation be based on response to chemotherapy?Cancer, 2003
- Combined-Modality Treatment and Selective Organ Preservation in Invasive Bladder Cancer: Long-Term ResultsJournal of Clinical Oncology, 2002
- Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancerUrology, 2002
- Transurethral Resection of Muscle-Invasive Bladder Cancer: 10-Year OutcomeJournal of Clinical Oncology, 2001
- CAN p53 HELP SELECT PATIENTS WITH INVASIVE BLADDER CANCER FOR BLADDER PRESERVATION?Journal of Urology, 1999
- Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: ten-year outcome.Journal of Clinical Oncology, 1998